Healthcare provider profile · identity verified

Allan Chen, MD

Internal Medicine · LOS ANGELES, CA · NPI 1003829326

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	851	276
Amlodipine Besylate	Amlodipine Besylate	502	176
Losartan Potassium	Losartan Potassium	342	116
Rosuvastatin Calcium	Rosuvastatin Calcium	314	109
Lisinopril	Lisinopril	271	84
Metformin Hcl Er	Metformin Hcl	261	94
Omeprazole	Omeprazole	237	97
Levothyroxine Sodium	Levothyroxine Sodium	231	72
Atenolol	Atenolol	204	65
Potassium Chloride	Potassium Chloride	196	71
Metoprolol Tartrate	Metoprolol Tartrate	169	52
Hydrochlorothiazide	Hydrochlorothiazide	168	60
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	167	42
Tamsulosin Hcl	Tamsulosin Hcl	167	62
Furosemide	Furosemide	145	57
Gabapentin	Gabapentin	131	53
Glipizide	Glipizide	128	46
Pravastatin Sodium	Pravastatin Sodium	128	45
Trazodone Hcl	Trazodone Hcl	128	42
Albuterol Sulfate Hfa	Albuterol Sulfate	126	66
Metformin Hcl	Metformin Hcl	123	46
Ozempic	Semaglutide	123	20
Pradaxa	Dabigatran Etexilate Mesylate	115	30
Famotidine	Famotidine	109	35
Ezetimibe	Ezetimibe	105	41
Pantoprazole Sodium	Pantoprazole Sodium	102	31
Bisoprolol Fumarate	Bisoprolol Fumarate	98	35
Zolpidem Tartrate	Zolpidem Tartrate	94	16
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	89	31
Jardiance	Empagliflozin	88	34
Alendronate Sodium	Alendronate Sodium	87	31
Clonazepam	Clonazepam	83	16
Hydralazine Hcl	Hydralazine Hcl	82	30
Lorazepam	Lorazepam	80	28
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	76	26
Allopurinol	Allopurinol	75	27
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	69	23
Finasteride	Finasteride	68	21
Duloxetine Hcl	Duloxetine Hcl	64	20
Ondansetron Odt	Ondansetron	60	12
Spiriva Respimat	Tiotropium Bromide	60	19
Terazosin Hcl	Terazosin Hcl	60	22
Tramadol Hcl	Tramadol Hcl	59	16
Meloxicam	Meloxicam	57	40
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	55	55
Simvastatin	Simvastatin	54	21
Clopidogrel	Clopidogrel Bisulfate	52	19
Spironolactone	Spironolactone	51	18
Carvedilol	Carvedilol	50	14
Isosorbide Mononitrate Er	Isosorbide Mononitrate	50	14
Eliquis	Apixaban	49	19
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	49	22
Lovastatin	Lovastatin	45	15
Triamcinolone Acetonide	Triamcinolone Acetonide	43	32
Colchicine	Colchicine	42	19
Prednisone	Prednisone	41	29
Mirtazapine	Mirtazapine	40	18
Acetaminophen-Codeine	Acetaminophen With Codeine	39	suppressed
Tradjenta	Linagliptin	39	16
Montelukast Sodium	Montelukast Sodium	38	15
Fluticasone Propionate	Fluticasone Propionate	36	18
Humulin N Kwikpen	Insulin Nph Human Isophane	35	12
Humulin N	Insulin Nph Human Isophane	34	12
Temazepam	Temazepam	34	suppressed
Estradiol	Estradiol	33	14
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	32	32
Escitalopram Oxalate	Escitalopram Oxalate	32	suppressed
Ibuprofen	Ibuprofen	31	suppressed
Humulin R	Insulin Regular, Human	29	14
Alvesco	Ciclesonide	28	13
Metoprolol Succinate	Metoprolol Succinate	28	suppressed
Hydrocortisone	Hydrocortisone	27	12
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	27	13
Eszopiclone	Eszopiclone	26	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	26	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	26	12
Acyclovir	Acyclovir	25	12
Benazepril Hcl	Benazepril Hcl	24	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	24	12
Fluoxetine Hcl	Fluoxetine Hcl	24	suppressed
Xarelto	Rivaroxaban	24	suppressed
Spironolactone-Hctz	Spironolact/Hydrochlorothiazid	23	suppressed
Oxycodone Hcl	Oxycodone Hcl	22	suppressed
Diazepam	Diazepam	21	suppressed
Lidocaine	Lidocaine	21	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	21	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	21	suppressed
Myrbetriq	Mirabegron	20	suppressed
Baclofen	Baclofen	19	suppressed
Chlorthalidone	Chlorthalidone	19	suppressed
Donepezil Hcl	Donepezil Hcl	19	suppressed
Clobetasol Propionate	Clobetasol Propionate	18	suppressed
Azelastine Hcl	Azelastine Hcl	17	11
Citalopram Hbr	Citalopram Hydrobromide	17	suppressed
Humalog Kwikpen U-100	Insulin Lispro	17	suppressed
Propranolol Hcl	Propranolol Hcl	16	suppressed
Nifedipine Er	Nifedipine	15	suppressed
Sertraline Hcl	Sertraline Hcl	15	suppressed
Veo Insulin Syringe	Syrge-Ndl,ins 0.3 Ml Half Mark	15	suppressed
Verapamil Er	Verapamil Hcl	15	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	14	suppressed
Lactulose	Lactulose	14	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	14	suppressed
Azithromycin	Azithromycin	13	12
Breyna	Budesonide/Formoterol Fumarate	13	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	13	suppressed
Felodipine Er	Felodipine	13	suppressed
Fenofibrate	Fenofibrate	13	suppressed
Morphine Sulfate Er	Morphine Sulfate	13	suppressed
Ketoconazole	Ketoconazole	12	suppressed
Nitroglycerin	Nitroglycerin	12	suppressed
Ondansetron Hcl	Ondansetron Hcl	12	suppressed
Trospium Chloride	Trospium Chloride	12	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	12	suppressed
Cefadroxil	Cefadroxil	11	11
Glyburide	Glyburide	11	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	11	suppressed
Mounjaro	Tirzepatide	11	suppressed
Warfarin Sodium	Warfarin Sodium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error